IGM Biosciences, Inc.
IGMS evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Lead Asset:
- IGM-2644 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for IGMS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
IGM-2644 (Phase 2)
Next Catalyst
—
Tracking 1 pipeline candidate · 83 clinical trials for IGM Biosciences, Inc..
Run IGM Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IGM Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is IGM Biosciences, Inc.'s lead drug candidate?
IGM Biosciences, Inc.'s most advanced tracked candidate is IGM-2644 (Phase 2) for Autoimmune diseases targeting antibody-secreting plasma cells.
Who is the CEO of IGM Biosciences, Inc.?
Chief Executive Officer is the chief executive officer of IGM Biosciences, Inc. (IGMS).
What therapeutic areas does IGM Biosciences, Inc. focus on?
IGM Biosciences, Inc. develops therapies across Oncology, Neurology, Immunology, Infectious Disease, Respiratory, Dermatology, Nephrology, Musculoskeletal, Gastroenterology, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.